Clinical trials: Neoadjuvant Treatment
Breast Cancer, Chemotherapeutic Agent Toxicity
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
RATIONALE: G-CSF may prevent or reduce febrile neutropenia in women receiving chemotherapy for breast cancer. It is not yet known which G-CSF regimen is more effective in preventing neutropenia.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neutropenia
- Trial name
- NCT00771433
- Testing
- filgrastim
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Francois Baclesse
Pancreatic Adenocarcinoma Resectable, Non Metastatic
Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.
This is an open master platform trial, which includes multi neo-adjuvant treatment trials, multi-center, national. This platform trial evaluates the major pathological response rate (mPR) after surgery.
- Conditions
- Pancreatic Adenocarcinoma Resectable, Non Metastatic, ECOG Performance Status Score of 0 or 1
- Trial name
- POWER (NCT07808567)
- Testing
- GnP, FOLFIRINOX
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Invasive Breast Carcinoma
Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer
This early phase I trial evaluates the impact of chemotherapy before surgery (neoadjuvant) on the peripheral blood immune phenotype in patients with operable breast cancer.
- Trial name
- ENHANCE (NCT04897009)
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Non-Small Cell Lung Cancer
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.
- Trial name
- NCT07256509
- Testing
- SYS6010, Osimertinib, Pemetrexed
- Volunteers
- 120 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Breast Cancer
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of trastuzumab emtansine (T-DM1) plus lapatinib (L)followed by abraxane (A) versus trastuzumab plus pertuzumab followed by paclitaxel…
- Trial name
- TEAL (NCT02073487)
- Testing
- T-DM1, Trastuzumab, Lapatinib
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- The Methodist Hospital Research Institute
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer
neoPEHP is a multicohort, open-label, exploratory, phase 2 study. Patients were eligible if they had previously untreated, histologically confirmed, unilateral, invasive, HER2-positive, ER-positive breast cancer and were suitable…
- Trial name
- NCT04858516
- Testing
- palbociclib and exemestane plus trastuzumab and pyrotinib
- Volunteers
- 57 people
- Sponsor
- Guangdong Provincial People's Hospital
Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
The goal of this multicenter randomized controlled phase III trial is to compare two durations of neoadjuvant chemotherapy (NAT) with mFOLFIRINOX or gemcitabine-nab-paclitaxel (GnP) before attempt for surgical resection in…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer, Neoadjuvant Chemotherapy
- Trial name
- ADVANTAGE (NCT06714604)
- Testing
- FOLFIRINOX or gemcitabine-nab-paclitaxel
- Where
- Sweden
- Volunteers
- 432 people
- Sponsor
- Sahlgrenska University Hospital
Non Small Cell Lung Cancer
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.
- Trial name
- NCT00986284
- Testing
- gefitinib
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Acute Myeloid Leukemia
Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia
Study Design: Treatment, Randomized, Open Label, Parallel Assignment This study is an open randomized and controlled trial aiming at assessing the efficacy and safety of Idarubicin (IDA) at different doses of 8mg/m2 and 10mg/m2…
- Trial name
- NCT02277847
- Testing
- Idarubicin(8mg/m2) and cytosine arabinoside, Idarubicin(10mg/m2), cytosine arabinoside
- Volunteers
- 400 people
- Sponsor
- Guangdong Provincial People's Hospital
Rectal Cancer
Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer
This trial examines the feasibility, effectiveness and safety of a combination of radiotherapy (over a period of five weeks) and chemotherapy (with 5-FU or Capecitabine and Oxaliplatin) and 10 fractions of deep regional…
- Trial name
- HyRec (NCT01716949)
- Testing
- Radiotherapy, Hyperthermia, 5-Fluorouracil
- Where
- 6 sites in Germany
- Volunteers
- 59 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Squamous Cell Carcinoma of the Head and Neck
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
There are currently no useful tests to identify patients who will respond to cetuximab therapy, notably because EGFR levels do not correlate with the clinical responses observed.
- Trial name
- NCT01218048
- Testing
- Cetuximab, Surgery, Post-surgical radiation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Robert Ferris
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
2-Drug Combination Chemotherapy Followed by Radiotherapy. Paclitaxel, TAX, NSC-125973; Cisplatin, CDDP, NSC-119875; followed by chest irradiation using 4-15 MV photons.
- Trial name
- NCT00001499
- Testing
- paclitaxel, cisplatin, chest radiotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for multiple myeloma.
- Trial name
- NCT00006232
- Testing
- dexamethasone, doxorubicin hydrochloride, idarubicin
- Where
- 12 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- West of Scotland Lymphoma Group
Head and Neck Squamous Cell Carcinoma
Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma （neoHNSCC）
This is a retrospective, single-arm study that assesses the efficacy and safety of neoadjuvant immunotherapy combined with platinum-based chemotherapy for Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT06011993
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Osteosarcoma, Ewing Sarcoma
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2…
- Conditions
- Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor
- Trial name
- NCT05302921
- Testing
- Cryoablation Therapy, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's National Research Institute
Non-small Cell Lung Cancer
Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy
This study proposes to evaluate the safety and efficacy of an anti-PD-L1 (durvalumab) agent as neoadjuvant therapy in patients diagnosed with localized NSCLC who are planned to undergo radical RT or CRT.
- Trial name
- IDEAR (NCT05267392)
- Testing
- Durvalumab, standard of care RT/RCT
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- Instituto Portugues de Oncologia, Francisco Gentil, Porto
Lung Cancer
MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)
This is an open-label, multi-center, randomized, phase III study. It is aimed to firstly evaluate the effectiveness and safety of almonertinib induction therapy in EGFR-mutated patients with unresectable stage III non-small cell…
- Trial name
- APPROACH (NCT04841811)
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-small Cell Lung Cancer
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
AK104, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy.
- Trial name
- NCT05377658
- Testing
- AK104, Albumin-Bound Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Henan Cancer Hospital
Locally Advanced Rectal Carcinoma
Radiological Markers in Locally Advanced Rectal Cancer
The goal of this observational study is to evaluate the prognostic significance of radiological markers, including the Likert Score derived from diffusion-weighted MRI (DWI), in patients with locally advanced rectal cancer (LARC)…
- Trial name
- LARC (NCT06843655)
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- IRCCS San Raffaele
Breast Cancer
Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer
This is a phase IV, prospective, single-center, open-label, randomized, controlled study. Eligible patients are randomly assigned into three groups.
- Trial name
- NCT01199432
- Testing
- 5-FU（intravenous infusion）+epirubicin+cyclophosphamide, 5-FU（intravenous bolus）+epirubicin+cyclophosphamide, epirubicin+cyclophosphamide
- Where
- China
- Volunteers
- 501 people
- Sponsor
- Tao OUYANG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.